Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review.

ABSTRACT:

Introduction

Globally about 1.7 million children were living with HIV in 2020. Two integrase strand transfer inhibitors, dolutegravir and raltegravir, are increasingly used in children. We conducted a systematic review to assess the effectiveness and safety of dolutegravir and raltegravir in children and adolescents living with HIV, aged 0-19 years.

Methods

Sources included MEDLINE, Embase, the Cochrane Library, clinical trial registries, abstracts from key conferences and reference list searching. Observational studies and clinical trials published January 2009-March 2021 were eligible. Outcomes included efficacy/effectiveness (CD4 counts and viral load) and/or safety outcomes (mortality, grade 3/4 adverse events and treatment discontinuation) through 6 months or more post-

SUBMITTER: Townsend CL 

PROVIDER: S-EPMC9663860 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature